The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
April 29th 2025
A 15-mg dose with a corticosteroid taper regimen was superior to placebo in sustained remission from week 12 to 52.
Vyvanse Receives FDA Priority Review for Expanded Binge Eating Disorder Indication
September 16th 2014The FDA has granted priority review to a supplemental New Drug Application that would expand the use of lisdexamfetamine dimesylate (Vyvanse) to treat adult patients with binge eating disorder.
Read More